Publicaciones en las que colabora con Juan Rafael Haba Rodríguez (7)

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2020

  1. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2017

  1. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1454-1461

  2. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

2013

  1. SEOM clinical guidelines for the management of metastatic breast cancer 2013

    Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1004-1010

2010

  1. SEOM clinical guidelines for the treatment of metastatic breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 719-723